China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strengthened partnership with the government of Guizhou province. This collaboration expands upon previous achievements in promoting cooperation in biomedicine, traditional Chinese medicine R&D, and the construction of grassroots public health systems.
Comprehensive Cooperation in Pharmaceutical and Healthcare
The two parties have agreed to conduct comprehensive and in-depth cooperation in the fields of pharmaceutical trade circulation, pharmaceutical industry, and comprehensive services. Sinopharm is set to leverage its nationwide pharmaceutical and health industry chain capabilities, aligning its development strategy with Guizhou’s resource endowment to increase investment and industrial layout in the province.
Investment and Industrial Layout in Guizhou
Sinopharm will deepen practical cooperation in biological products, modern Chinese medicine, medical healthcare, big health products, and tax exemption sectors. The company aims to continuously promote the implementation of related projects, further integrating its expertise with local resources to enhance the healthcare industry in Guizhou.
Continuous Promotion of Healthcare Projects
This partnership underscores Sinopharm’s commitment to driving forward healthcare initiatives in Guizhou. The collaboration is expected to lead to significant developments in the region’s pharmaceutical industry and public health services, building on the success of previous joint efforts.-Fineline Info & Tech
